Loxo Oncology, Inc.

This study tests a new drug, LOXO-305, against two standard treatment combinations for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has already been treated with a BTK inhibitor. About 238 participants will be randomly assigned t…

This study tests a new drug called pirtobrutinib against other approved drugs for mantle cell lymphoma, a type of blood cancer. About 500 people who have already received at least one prior treatment will be randomly assigned to receive either pirtobrutinib or a standard BTK inhi…

This study tests whether adding a new targeted drug, pirtobrutinib, to the standard combination of venetoclax and rituximab helps people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) live longer without their cancer getting worse. About 600 adults wh…

This study tests whether a daily pill called pirtobrutinib works better than the standard chemo-immunotherapy combination (bendamustine + rituximab) for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have not yet been treated. About 309 participants wi…

This study tests whether a new drug called selpercatinib works better than standard treatments for people with a rare type of thyroid cancer (medullary thyroid cancer) that has a specific gene change (RET mutation) and has spread or cannot be removed by surgery. About 291 adults …